Janux Therapeutics, Inc. (JANX) Current Ratio
- Current ratio · latest quarter: Value 16.35×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.35× | Current assets / current liabilities. $983.34M ÷ $60.15M ≈ 16.35× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 983.34M USD | Assets, Current |
| Current obligations | 60.15M USD | Liabilities, Current |
| Cash and equivalents | 27.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $983.34M | $60.15M | $27.77M | (m) | (m) | (m) | $3.02M | (m) | 16.35× |
| 2026-03-31 | $1.00B | $58.91M | $51.83M | (m) | (m) | (m) | $3.38M | (m) | 17.01× |
| 2025-12-31 | $975.89M | $25.00M | $52.33M | (m) | (m) | (m) | $4.97M | (m) | 39.04× |
| 2025-09-30 | $998.09M | $27.83M | $48.39M | (m) | (m) | (m) | $3.40M | (m) | 35.86× |
| 2025-06-30 | $1.01B | $21.38M | $52.45M | (m) | (m) | (m) | $3.48M | (m) | 47.03× |
| 2025-03-31 | $1.02B | $17.50M | $73.74M | (m) | (m) | (m) | $2.35M | (m) | 58.47× |
| 2024-12-31 | $1.03B | $17.46M | $430.61M | (m) | (m) | (m) | $4.03M | (m) | 59.21× |
| 2024-09-30 | $666.32M | $17.17M | $26.75M | (m) | (m) | (m) | $2.46M | (m) | 38.80× |
| 2024-06-30 | $661.94M | $11.54M | $14.66M | (m) | $7.50M | (m) | $1.25M | (m) | 57.34× |
| 2024-03-31 | $658.67M | $10.61M | $212.80M | (m) | $519.00K | (m) | $2.25M | (m) | 62.09× |
| 2023-12-31 | $349.24M | $13.03M | $19.20M | (m) | (m) | (m) | $2.42M | (m) | 26.80× |
| 2023-09-30 | $355.19M | $14.47M | $17.15M | (m) | $0.00 | (m) | $2.50M | (m) | 24.55× |
| 2023-06-30 | $309.30M | $17.90M | $33.70M | (m) | $0.00 | (m) | $1.91M | (m) | 17.28× |
| 2023-03-31 | $321.40M | $16.11M | $30.36M | (m) | $750.00K | (m) | $2.05M | (m) | 19.95× |
| 2022-12-31 | $332.44M | $16.51M | $51.43M | (m) | $0.00 | (m) | $2.16M | (m) | 20.14× |
| 2022-09-30 | $344.33M | $16.34M | $64.75M | (m) | $500.00K | (m) | $2.87M | (m) | 21.08× |
| 2022-06-30 | $358.06M | $12.99M | $58.40M | (m) | $0.00 | (m) | $3.00M | (m) | 27.56× |
| 2022-03-31 | $364.65M | $12.52M | $55.13M | (m) | $0.00 | (m) | $1.94M | (m) | 29.14× |
| 2021-12-31 | $377.02M | $12.80M | $35.58M | (m) | $0.00 | (m) | $2.46M | (m) | 29.46× |
| 2021-09-30 | $389.59M | $12.47M | $39.39M | (m) | $0.00 | (m) | $3.61M | (m) | 31.24× |
| 2021-06-30 | $396.61M | $9.21M | $251.63M | (m) | $375.00K | (m) | $354.00K | (m) | 43.09× |
| 2020-12-31 | $16.06M | $3.18M | $7.81M | (m) | $8.00M | (m) | $428.00K | (m) | 5.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |